News from janssen r A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Nov 24, 2014, 16:30 ET

Janssen Submits New Drug Application for YONDELIS® (trabectedin) to U.S. FDA for the Treatment of Patients with Advanced Soft Tissue Sarcoma

 Janssen Research & Development, LLC (Janssen) has submitted a New Drug Application (NDA) for YONDELIS® (trabectedin) to the U.S. Food...

Nov 19, 2014, 09:00 ET

Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate

Janssen Research & Development, LLC (Janssen) today announced the submission of a New Drug Application (NDA) for three-month atypical...

Nov 18, 2014, 06:00 ET

Janssen reicht Antrag auf Zulassung von SIMPONI® für nicht-radiografische axiale Spondyloarthritis in der Europäischen Union ein

 Janssen Biologics B.V. (Janssen) gab heute bekannt, man habe eine Typ II-Variation bei der Europäischen Arzneimittelagentur auf Zulassung...

Nov 18, 2014, 06:00 ET

Janssen dépose une demande en vue de l'approbation de SIMPONI® dans l'Union européenne pour le traitement de la spondylarthrite axiale sans signe radiographique

 Janssen Biologics B.V. (Janssen) a annoncé aujourd'hui qu'une variation de type II avait été déposée auprès de...

Nov 13, 2014, 08:45 ET

U.S. FDA Approves Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) for the Treatment of Schizoaffective Disorder

Janssen Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Applications...

Nov 07, 2014, 19:06 ET
Janssen Logo.

Janssen Highlights its Hepatitis C Clinical Development Program in Advance of 2014 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Janssen R&D Ireland (Janssen) highlights its hepatitis C (HCV) clinical development program in advance of The Liver Meeting®, the Annual...

Nov 06, 2014, 09:54 ET

Janssen to Demonstrate Breadth of Oncology Portfolio with 41 Clinical Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting

Janssen Research & Development, LLC (Janssen) will present new data across more than eight disease areas at the 56th American Society of...

Nov 06, 2014, 03:00 ET

Janssen Collaborates for Continued Evaluation of Multidrug-Resistant Tuberculosis Treatment Regimens with SIRTURO® (bedaquiline)

Janssen Research & Development, LLC (Janssen) today announced a collaboration with the International Union Against Tuberculosis and Lung...

Nov 05, 2014, 16:48 ET
OLYSIO(R) (simeprevir) Logo

OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection

Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved OLYSIO®...

Oct 27, 2014, 08:00 ET
Sunny Anderson, celebrity cook, television host and ulcerative colitis patient

Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign

Janssen Biotech, Inc. and the Crohn's & Colitis Foundation of America (CCFA) announced today the launch of Get Your Full Course, an educational...

Oct 20, 2014, 16:05 ET

Janssen Pharmaceuticals and Diabetes Hands Foundation Encourage People with Type 2 Diabetes to Get Moving for National Diabetes Month

Janssen Pharmaceuticals, Inc. has teamed up with the Diabetes Hands Foundation to raise awareness about the importance of incorporating...

Oct 20, 2014, 08:05 ET

IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for...

Oct 20, 2014, 05:08 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

Europäische Kommission erteilt IMBRUVICA™ die Zulassung für zwei Arten von Blutkrebs

Erstklassiger BTK-Inhibitor für die komplizierten seltenen Krankheiten CLL und MCL Janssen-Cilag International NV (Janssen) gab heute...

Oct 20, 2014, 05:06 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

La Commission européenne approuve IMBRUVICA™ pour le traitement de deux types de cancer du sang

Premier inhibiteur de la tyrosine-kinase de Burton de sa catégorie pour le traitement des maladies orphelines complexes que sont la LLC et...

Oct 17, 2014, 14:06 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

La Comisión Europea aprueba IMBRUVICA™ para dos cánceres sanguíneos

Primer inhibidor BTK de su clase para las enfermedades huérfanas complejas CLL y MCL  Janssen-Cilag International NV (Janssen) ha...

Oct 13, 2014, 10:19 ET

Janssen beantragt Zulassung von STELARA® zur Behandlung von Plaque-Psoriasis im Kindesalter in der Europäischen Union

 Janssen-Cilag International NV (Janssen) gab heute bekannt, bei der Europäischen Arzneimittel-Agentur eine Typ-II-Variation beantragt zu...

Oct 12, 2014, 16:47 ET

Janssen soumet une demande en vue de faire approuver STELARA® dans l'Union européenne pour le traitement du psoriasis en plaques de l'enfant

 Janssen-Cilag International NV (Janssen) a annoncé aujourd'hui qu'une modification de Type II a été déposée...

Oct 10, 2014, 10:05 ET

Janssen envía su aplicación que busca la aprobación de STELARA® en la Unión Europea para soriasis de placa pediátrica

 Janssen-Cilag International NV (Janssen) anunció hoy que se ha cumplimentado una variación de tipo II con la Agencia Europea de...

Oct 09, 2014, 21:37 ET

Neue Ergebnisse aus Längsschnittbewertung und Psoriasis-Register (PSOLAR) zeigen Unterschiede in Persistenz bei biologischen Therapien

-- Analyse von Beobachtungsstudie zeigt signifikant bessere Persistenz für STELARA® (Ustekinumab) im Vergleich mit Anti-TNFs bei...

Oct 09, 2014, 15:25 ET

Los nuevos descubrimientos del PSOLAR demuestran la diferente persistencia entre las terapias biológicas

-- Los nuevos descubrimientos del Psoriasis Longitudinal Assessment and Registry (PSOLAR) demuestran la diferente persistencia entre las terapias...